Literature DB >> 12213350

High prevalence of diabetes in patients with pancreatic cancer in central Anatolia, Turkey.

Mustafa Cetin1, Ramiz Colak, Fahri Bayram, Mustafa Altinbaş, Ali Unal, Fahrettin Keleştimur.   

Abstract

Tumor-induced pancreatic damage or insulin resistance may be responsible for diabetes in pancreatic cancer (PC) patients, but the exact cause of association remains controversial. In this study, we aimed to investigate the prevalence of diabetes in patients with PC in central Anatolia, Turkey, and to evaluate whether diabetes is caused by PC. A total of 40 patients with primary PC were enrolled in the study. 13 (32.5%) of the patients had diabetes before PC diagnosis. Oral glucose tolerance test was performed in the remaining 27 patients. The period between the diagnosis of diabetes and detection of PC was less than 1 year in seven (17.5%) patients who had previous diabetes. Recent-onset diabetes and impaired glucose tolerance were detected in 13 (32.5%) and two (5%) of the PC patients, respectively. The prevalence of recent-onset and shortly-before-diagnosed diabetes has been found very high (50%) in our patients with PC. Interestingly, we determined higher levels of insulin and C-peptide in PC patients having abnormal glucose tolerance than patients having normal glucose tolerance. In conclusion, as it has been reported in other population, we determined high prevalence of diabetes in PC patients in central Anatolia. High insulin and C-peptide level indicate that different mechanisms such as insulin resistance may be responsible for abnormal glucose tolerance in PC patients other than the tumor caused insulin deficiency.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213350     DOI: 10.1016/s0168-8227(02)00130-4

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  7 in total

1.  Does diabetes mellitus affect presentation, stage and survival in operable pancreatic cancer?

Authors:  Clement L K Chia; Anthea Y S Lee; Vishal G Shelat; Saleem Ahmed; Sameer P Junnarkar; Winston W L Woon; Jee-Keem Low
Journal:  Hepatobiliary Surg Nutr       Date:  2016-02       Impact factor: 7.293

2.  Impact of diabetes mellitus on treatment outcomes in patients with nasopharyngeal cancer.

Authors:  Hui Liu; Yunfei Xia; Nianji Cui
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Diabetic ketoacidosis in type 2 diabetics: a novel presentation of pancreatic adenocarcinoma.

Authors:  Ming Valerie Lin; Gene Bishop; Maria Benito-Herrero
Journal:  J Gen Intern Med       Date:  2010-01-30       Impact factor: 5.128

Review 4.  Diabetes and cancer I: risk, survival, and implications for screening.

Authors:  Adedayo A Onitilo; Jessica M Engel; Ingrid Glurich; Rachel V Stankowski; Gail M Williams; Suhail A Doi
Journal:  Cancer Causes Control       Date:  2012-05-03       Impact factor: 2.506

Review 5.  Diabetes mellitus: a risk factor for pancreatic cancer?

Authors:  M Yalniz; P M Pour
Journal:  Langenbecks Arch Surg       Date:  2004-04-09       Impact factor: 3.445

Review 6.  The Intricate Crosstalk Between Insulin and Pancreatic Ductal Adenocarcinoma: A Review From Clinical to Molecular.

Authors:  Junyuan Deng; Yujie Guo; Jiali Du; Jichun Gu; Lei Kong; Boan Tao; Ji Li; Deliang Fu
Journal:  Front Cell Dev Biol       Date:  2022-02-17

7.  Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study.

Authors:  Dominik J Ose; Richard Viskochil; Andreana N Holowatyj; Mikaela Larson; Dalton Wilson; William A Dunson; Vikrant G Deshmukh; J Ryan Butcher; Belinda R Taylor; Kim Svoboda; Jennifer Leiser; Benjamin Tingey; Benjamin Haaland; David W Wetter; Simon J Fisher; Mia Hashibe; Cornelia M Ulrich
Journal:  J Natl Compr Canc Netw       Date:  2021-03-10       Impact factor: 11.908

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.